AI Summary
Thinking
Thinking
We reviewed 3,884 live results for cuvitru immune globulin subcutaneous human 20 solution and narrowed them down to the 3 options that look most worth comparing first.
The options are Cuvitru [Immune Globulin Subcutaneous (Human), 20% Solution], XEMBIFY® (immune globulin subcutaneous, human–klhw) 20% and Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid).
Source: Takeda Healthcare Philippines, Inc.
Description
Cuvitru is a 200 mg/mL (20%) liquid protein solution indicated as replacement therapy for adults and pediatric patients (2 years and older) with primary humoral immunodeficiency (PI). This subcutaneous immunoglobulin (SCIG) treatment is designed for ready-to-use infusion with a maximum infusion rate of 60 mL/hr per site, allowing for flexible administration in clinical or home settings.
Best for
primary humoral immunodeficiency patients, pediatric patients 2 years and older, subcutaneous replacement therapy and home infusion management
Rate this product
Source: Xembify
Description
XEMBIFY is a sterile, 20% liquid solution of human immune globulin G (IgG) indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This subcutaneous immune globulin (SCIG) replacement therapy is available in single-use glass vials in multiple sizes, including 1 g, 2 g, 4 g, and 10 g, to accommodate flexible dosing requirements and home administration.
Best for
primary humoral immunodeficiency treatment, patients 2 years and older, subcutaneous infusion therapy and home self-administration
Rate this product
Source: CSL Behring
Description
Hizentra is the first and only 20% subcutaneous immunoglobulin (SCIg) therapy approved for the treatment of primary immunodeficiency (PI) and the maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). This human normal immunoglobulin solution is stabilized with L-proline and designed for convenient subcutaneous injection, allowing for patient self-administration at home with single-dose prefilled syringes or vials.
Best for
primary immunodeficiency patients, CIDP maintenance therapy, subcutaneous self-administration and home-based medical treatment
Rate this product
| Compare | #1Cuvitru [Immune Globulin Subcutaneous (Human), 20% Solution] | #2XEMBIFY® (immune globulin subcutaneous, human–klhw) 20% | #3Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) |
|---|---|---|---|
| Source | Takeda Healthcare Philippines, Inc. | Xembify | CSL Behring |
| Description | Cuvitru is a 200 mg/mL (20%) liquid protein solution indicated as replacement therapy for adults and pediatric patients (2 years and older) with primary humoral immunodeficiency (PI). This subcutaneous immunoglobulin (SCIG) treatment is designed for ready-to-use infusion with a maximum infusion rate of 60 mL/hr per site, allowing for flexible administration in clinical or home settings. | XEMBIFY is a sterile, 20% liquid solution of human immune globulin G (IgG) indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This subcutaneous immune globulin (SCIG) replacement therapy is available in single-use glass vials in multiple sizes, including 1 g, 2 g, 4 g, and 10 g, to accommodate flexible dosing requirements and home administration. | Hizentra is the first and only 20% subcutaneous immunoglobulin (SCIg) therapy approved for the treatment of primary immunodeficiency (PI) and the maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). This human normal immunoglobulin solution is stabilized with L-proline and designed for convenient subcutaneous injection, allowing for patient self-administration at home with single-dose prefilled syringes or vials. |
| Best for | primary humoral immunodeficiency patients, pediatric patients 2 years and older, subcutaneous replacement therapy and home infusion management | primary humoral immunodeficiency treatment, patients 2 years and older, subcutaneous infusion therapy and home self-administration | primary immunodeficiency patients, CIDP maintenance therapy, subcutaneous self-administration and home-based medical treatment |
| Action | Takeda Healthcare Philippines, Inc. | Xembify | CSL Behring |
| Rate this product |
"Cuvitru [Immune Globulin Subcutaneous (Human), 20% Solution] from Takeda Healthcare Philippines, Inc.."
TopFind picked this because As the official local representative of the manufacturer, Takeda ensures that Cuvitru is FDA-approved and meets all regulatory standards for treating primary immunodeficiency in the Philippines.
Note: TopFind AI compiles product and service information for general comparison purposes only.